Literature DB >> 24465523

Influence of aggregation and route of injection on the biodistribution of mouse serum albumin.

Grzegorz Kijanka1, Malgorzata Prokopowicz1, Huub Schellekens2, Vera Brinks1.   

Abstract

Protein aggregates are a major risk factor for immunogenicity. Until now most studies on aggregate-driven immunogenicity have focused on linking physicochemical features of the aggregates to the formation of anti-drug antibodies. Lacking is however, basic knowledge on the effect of aggregation on the biodistribution and clearance of therapeutic proteins in vivo. The aim of current study was to get insight into the effect of aggregation on biodistribution in mice using different routes of administration. Fluorescently labeled stressed and unstressed mouse serum albumin was injected via different routes in mice and detected via in vivo fluorescence imaging up to 48 hrs post-injection. We found that biodistribution of stressed MSA significantly differed from its unstressed counterpart. Subcutaneous and intramuscular administration resulted in accumulation of protein at the site of injection, from which clearance of stressed MSA was considerably slower than clearance of unstressed MSA. Upon intravenous and intraperitoneal injection of stressed MSA, fluorescent "hotspots" were observed in the spleens, livers and lungs. Further and more detailed examination of biodistribution after intraperitoneal injection showed higher fluorescence in most of tested organs suggesting more efficient diffusion and/or lymphatic uptake from peritoneum of unstressed MSA than the stressed formulation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24465523      PMCID: PMC3898957          DOI: 10.1371/journal.pone.0085281

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  19 in total

Review 1.  Lymphatic transport of proteins after s.c. injection: implications of animal model selection.

Authors:  C J Porter; G A Edwards; S A Charman
Journal:  Adv Drug Deliv Rev       Date:  2001-08-23       Impact factor: 15.470

2.  Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.

Authors:  A Bertolotto; S Malucchi; E Milano; A Castello; M Capobianco; R Mutani
Journal:  Immunopharmacology       Date:  2000-07-20

Review 3.  Factors influencing the immunogenicity of therapeutic proteins.

Authors:  Huub Schellekens
Journal:  Nephrol Dial Transplant       Date:  2005-06       Impact factor: 5.992

4.  Hepatic uptake of albumin-bound substances: albumin receptor concept.

Authors:  R K Ockner; R A Weisiger; J L Gollan
Journal:  Am J Physiol       Date:  1983-07

5.  Role of aggregated human growth hormone (hGH) in development of antibodies to hGH.

Authors:  W V Moore; P Leppert
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

6.  Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats.

Authors:  N R Srinivas; W C Shyu; R S Weiner; G Warner; C Comereski; L K Tay; D S Greene; R H Barbhaiya
Journal:  Pharm Res       Date:  1997-07       Impact factor: 4.200

7.  Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice.

Authors:  A Braun; L Kwee; M A Labow; J Alsenz
Journal:  Pharm Res       Date:  1997-10       Impact factor: 4.200

8.  Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH-deficient patients.

Authors:  T Laursen; J Møller; J O Jørgensen; H Orskov; J S Christiansen
Journal:  Clin Endocrinol (Oxf)       Date:  1996-09       Impact factor: 3.478

Review 9.  Immunogenicity of recombinant human proteins: causes and consequences.

Authors:  Huub Schellekens; Nicole Casadevall
Journal:  J Neurol       Date:  2004-06       Impact factor: 4.849

10.  Effect of treatment regimen on the immunogenicity of human interferon Beta in immune tolerant mice.

Authors:  Grzegorz Kijanka; Wim Jiskoot; Huub Schellekens; Vera Brinks
Journal:  Pharm Res       Date:  2013-01-30       Impact factor: 4.200

View more
  5 in total

1.  Investigation of the immunogenicity of different types of aggregates of a murine monoclonal antibody in mice.

Authors:  Angelika J Freitag; Maliheh Shomali; Stylianos Michalakis; Martin Biel; Michael Siedler; Zehra Kaymakcalan; John F Carpenter; Theodore W Randolph; Gerhard Winter; Julia Engert
Journal:  Pharm Res       Date:  2014-08-15       Impact factor: 4.200

Review 2.  Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges.

Authors:  Wim Jiskoot; Grzegorz Kijanka; Theodore W Randolph; John F Carpenter; Atanas V Koulov; Hanns-Christian Mahler; Marisa K Joubert; Vibha Jawa; Linda O Narhi
Journal:  J Pharm Sci       Date:  2016-04-01       Impact factor: 3.534

3.  Antibiotic Therapy Using Phage Depolymerases: Robustness Across a Range of Conditions.

Authors:  Han Lin; Matthew L Paff; Ian J Molineux; James J Bull
Journal:  Viruses       Date:  2018-11-12       Impact factor: 5.048

Review 4.  Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins.

Authors:  Nicole L Jarvi; Sathy V Balu-Iyer
Journal:  BioDrugs       Date:  2021-02-01       Impact factor: 5.807

Review 5.  Protein nanoparticles directed cancer imaging and therapy.

Authors:  Yao Miao; Tao Yang; Shuxu Yang; Mingying Yang; Chuanbin Mao
Journal:  Nano Converg       Date:  2022-01-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.